South Korean drug company SK Bioscience aims to seek a domestic stock market listing in the first half of next year, it said on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
